Diane Young
Chief Tech/Sci/R&D Officer bei CELLDEX THERAPEUTICS, INC.
Vermögen: 2 Mio $ am 31.03.2024
Profil
Diane C.
Young is currently the Chief Medical Officer & Senior Vice President at Celldex Therapeutics, Inc. and a Trustee at The Valerie Fund.
She previously worked as the Assistant Director-Clinical Investigation II at Hoffmann-La Roche, Inc. from 1988 to 1990, Director-Clinical Research at Sandoz Research Institute from 1991 to 1993, Vice President-Global Development at R.W.
Johnson Pharmaceutical Research Institute from 1992 to 2002, Head-Oncology Clinical Development at Novartis Oncology, Inc., and Chief Medical Officer & Vice President at GTx, Inc. from 2015 to 2019.
She received her undergraduate degree from Harvard University and her doctorate from Harvard Medical School.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 15.06.2023 | 47 115 ( 0,07% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von Diane Young
| Unternehmen | Position | Beginn |
|---|---|---|
| CELLDEX THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 08.07.2019 |
The Valerie Fund
 The Valerie Fund Miscellaneous Commercial ServicesCommercial Services The Valerie Fund operates as a cancer treatment center. It provides comprehensive care to children with cancer and blood disorders. The company was founded by Ed Goldstein and Sue Goldstein in 1977 and is headquartered in Maplewood, NJ. | Director/Board Member | - |
Ehemalige bekannte Positionen von Diane Young
| Unternehmen | Position | Ende |
|---|---|---|
GTx, Inc.
 GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Chief Tech/Sci/R&D Officer | 01.02.2019 |
| R.W. Johnson Pharmaceutical Research Institute | Corporate Officer/Principal | 01.11.2002 |
| Sandoz Research Institute | Corporate Officer/Principal | 01.01.1993 |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Corporate Officer/Principal | 01.01.1990 |
Novartis Oncology, Inc.
 Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Corporate Officer/Principal | - |
Ausbildung von Diane Young
| Harvard University | Undergraduate Degree |
| Harvard Medical School | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Private Unternehmen | 6 |
|---|---|
GTx, Inc.
GTx, Inc. Pharmaceuticals: MajorHealth Technology GTx, Inc. is a a biopharmaceutical company, which engages in the discovery, development, and commercialization of small molecules for the treatment of muscle-related diseases and other serious medical conditions. It focuses on developing selective androgen receptor modulators and selective androgen receptor degrader for the treatment of breast cancer, stress urinary incontinence, Duchenne muscular dystrophy, and prostate cancer. The company was founded by Marc Steven Hanover and Mitchell Shuster Steiner on September 24, 1997 and is headquartered in Memphis, TN. | Health Technology |
Novartis Oncology, Inc.
Novartis Oncology, Inc. Pharmaceuticals: MajorHealth Technology Novartis Oncology, Inc. provides healthcare solutions. The firm offers medicines, eye care and generic pharmaceuticals. It also offers patient declaration, patient support and assistance, and additional resources. The company is headquartered in East Hanover, NJ. | Health Technology |
Hoffmann-La Roche, Inc.
Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
| R.W. Johnson Pharmaceutical Research Institute | |
| Sandoz Research Institute | |
The Valerie Fund
The Valerie Fund Miscellaneous Commercial ServicesCommercial Services The Valerie Fund operates as a cancer treatment center. It provides comprehensive care to children with cancer and blood disorders. The company was founded by Ed Goldstein and Sue Goldstein in 1977 and is headquartered in Maplewood, NJ. | Commercial Services |
